Editas Medicine, Inc. 4
4 · Editas Medicine, Inc. · Filed Feb 16, 2017
Insider Transaction Report
Form 4
Glucksmann Alexandra
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2017-02-15$0.65/sh+6,000$3,900→ 123,788 total - Sale
Common Stock
2017-02-15$20.00/sh−5,000$100,000→ 118,788 total - Exercise/Conversion
Stock Option (right to buy)
2017-02-15−6,000→ 31,461 totalExercise: $0.65Exp: 2025-04-15→ Common Stock (6,000 underlying) - Sale
Common Stock
2017-02-15$23.48/sh−1,000$23,484→ 117,788 total
Footnotes (2)
- [F1]The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 13, 2016.
- [F2]This option was granted on April 16, 2015 and is scheduled to vest over four years with 25% of the shares having vested on March 9, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through March 9, 2019.